SYNTHESIS AND SEROTONERGIC ACTIVITY OF 5-(OXADIAZOLYL)TRYPTAMINES - POTENT AGONISTS FOR 5-HT(1D) RECEPTORS

被引:87
作者
STREET, LJ
BAKER, R
CASTRO, JL
CHAMBERS, MS
GUIBLIN, AR
HOBBS, SC
MATASSA, VG
REEVE, AJ
BEER, MS
MIDDLEMISS, DN
NOBLE, AJ
STANTON, JA
SCHOLEY, K
HARGREAVES, RJ
机构
[1] MERCK SHARP & DOHME LTD,NEUROSCI RES CTR,DEPT BIOCHEM,HARROW CM20 2QR,ESSEX,ENGLAND
[2] MERCK SHARP & DOHME LTD,NEUROSCI RES CTR,DEPT PHARMACOL,HARROW CM20 2QR,ESSEX,ENGLAND
关键词
D O I
10.1021/jm00063a003
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
The synthesis and 5-HT1D receptor activity of a novel series of 5-(oxadiazolyl)tryptamines is described. Modifications of the oxadiazole 3-substituent, length of the linking chain (n), and the amine substituents are explored and reveal a large binding pocket in the 5-HT1D receptor domain. Oxadiazole substituents such as benzyl are accommodated without loss of agonist potency or efficacy. The incorporation of polar functionality on a phenyl or benzyl spacer group results in a 10-fold increase in affinity and functional potency. Optimal 5-HT1D activity is observed when the heterocycle is conjugated with the indole and the benzyl sulfonamides 20t and 20u represent some of the most potent 5-HT1D agonists known. Replacement of O for S in the heterocycle leads to a further increase in potency. Deletion of oxadiazole N-2 does not reduce activity, suggesting the requirement for only one H-bond acceptor in this location. The selectivity of these compounds for 5-HT1D receptors over other serotonergic receptors is discussed. Sulfonamide 20t shows greater-than-or-equal-to 1000-fold selectivity for 5-HT1D over 5-HT2, 5-HT1C, and 5-HT3 receptors and 10-fold selectivity with respect to 5-HT1A receptors. The functional activity of this series of compounds is studied and demonstrates high 5-HT1D receptor potency and efficacy comparable to that of 5-HT.
引用
收藏
页码:1529 / 1538
页数:10
相关论文
共 34 条
[1]  
BAKER R, 1991, Patent No. 438230
[2]   AN INVESTIGATION OF THE 5-HT1D RECEPTOR-BINDING AFFINITY OF 5-HYDROXYTRYPTAMINE, 5-CARBOXYAMIDOTRYPTAMINE AND SUMATRIPTAN IN THE CENTRAL-NERVOUS-SYSTEM OF 7 SPECIES [J].
BEER, MS ;
STANTON, JA ;
BEVAN, Y ;
CHAUHAN, NS ;
MIDDLEMISS, DN .
EUROPEAN JOURNAL OF PHARMACOLOGY, 1992, 213 (02) :193-197
[3]   THE 5-HT4 RECEPTOR - A PLACE IN THE SUN [J].
BOCKAERT, J ;
FOZARD, JR ;
DUMUIS, A ;
CLARKE, DE .
TRENDS IN PHARMACOLOGICAL SCIENCES, 1992, 13 (04) :141-145
[4]   THE ANTIMIGRAINE DRUG, SUMATRIPTAN (GR43175), SELECTIVELY BLOCKS NEUROGENIC PLASMA EXTRAVASATION FROM BLOOD-VESSELS IN DURA MATER [J].
BUZZI, MG ;
MOSKOWITZ, MA .
BRITISH JOURNAL OF PHARMACOLOGY, 1990, 99 (01) :202-206
[5]  
CASTRO JL, IN PRESS BIO MED CHM
[6]   SUMATRIPTAN - A REVIEW OF ITS PHARMACODYNAMIC AND PHARMACOKINETIC PROPERTIES, AND THERAPEUTIC EFFICACY IN THE ACUTE TREATMENT OF MIGRAINE AND CLUSTER HEADACHE [J].
DECHANT, KL ;
CLISSOLD, SP .
DRUGS, 1992, 43 (05) :776-798
[7]  
DELEAN A, 1978, AM J PHYSIOL, V235, P97
[8]   THE SELECTIVE CAROTID ARTERIAL VASOCONSTRICTOR ACTION OF GR43175 IN ANESTHETIZED DOGS [J].
FENIUK, W ;
HUMPHREY, PPA ;
PERREN, MJ .
BRITISH JOURNAL OF PHARMACOLOGY, 1989, 96 (01) :83-90
[9]   THE DEVELOPMENT OF A HIGHLY SELECTIVE 5-HT(1) RECEPTOR AGONIST, SUMATRIPTAN, FOR THE TREATMENT OF MIGRAINE [J].
FENIUK, W ;
HUMPHREY, PPA .
DRUG DEVELOPMENT RESEARCH, 1992, 26 (03) :235-240
[10]   CONTROLLING THE OUTCOME OF A CARBOCATION-INITIATED CYCLIZATION [J].
FLEMING, I ;
PEARCE, A .
JOURNAL OF THE CHEMICAL SOCIETY-PERKIN TRANSACTIONS 1, 1981, (01) :251-255